Caicun Zhou, MD
Shanghai East Hospital · The East Hospital Affiliated to Tongji University, Shanghai, Shanghai 200120 · Shanghai Pulmonary Hospital, Shanghai, China
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
20
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in non-small cell lung cancer
0
PubMed author-name match
Trials
Studies that name Caicun Zhou, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:43 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07868172 · GST101 in Participants With RAS-Mutant Advanced Solid TumorsGenuine Seed Therapeutics (Zhuhai) Co., Ltd. · recruiting · RAS-mutant Advanced Solid Tumors · study chair
- Ph3NCT07383116 · Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung CancerShanghai Huaota Biopharmaceutical Co., Ltd. · not yet recruiting · Non Squamous Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT06631989 · A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung CancerWayshine Biopharm, Inc. · recruiting · EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer · principal investigator
- Ph1NCT06132828 · Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid TumorsZhejiang Doer Biologics Co., Ltd. · recruiting · Solid Tumor · principal investigator
- Ph3NCT05673590 · Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerBeijing Biostar Pharmaceuticals Co., Ltd. · unknown · Locally Advanced or Metastatic Non-Small Cell Lung Cancer · principal investigator
- Ph3NCT05487391 · A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.Qilu Pharmaceutical Co., Ltd. · recruiting · Carcinoma, Non-Small-Cell Lung · study chair
- Ph2/Ph3NCT05001724 · KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 AgentJiangsu Alphamab Biopharmaceuticals Co., Ltd · terminated · Advanced Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT04900363 · A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLCAkeso · completed · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT04474119 · KN046 in Subjects With Advanced Squamous Non-small Cell Lung CancerJiangsu Alphamab Biopharmaceuticals Co., Ltd · unknown · Squamous Non-small-cell Lung Cancer · principal investigator
- N/ANCT04360655 · Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLCShanghai Pulmonary Hospital, Shanghai, China · unknown · Effect Increased, Safety Issues · principal investigator
- Ph2NCT03838848 · KN046 in Patients With Advanced Non-small Cell Lung CancerJiangsu Alphamab Biopharmaceuticals Co., Ltd · terminated · Stage IV Non-small Cell Lung Cancer · principal investigator
- Ph3NCT03668496 · A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLCJiangsu HengRui Medicine Co., Ltd. · unknown · Lung Cancer Squamous Cell, Lung Cancer Stage IV, PD-1 Antibody · principal investigator
- Ph2NCT03002844 · EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismShanghai Pulmonary Hospital, Shanghai, China · unknown · Nonsmall Cell Lung Cancer, EGFR Gene Mutation · principal investigator
- Ph2NCT02930954 · Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation AbundanceCaicun Zhou · unknown · Non-small-cell Lung Cancer · principal investigator
- Ph3NCT02859077 · EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismShanghai Pulmonary Hospital, Shanghai, China · unknown · Non-Small-Cell Lung Cancer · principal investigator
- Ph2NCT02540824 · Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung CancerTongji University · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT02535507 · Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung CancerTongji University · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT02515435 · The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung CancerTongji University · unknown · Non-Small Cell Lung Cancer · principal investigator
- Ph3NCT02448797 · Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutationBetta Pharmaceuticals Co., Ltd. · unknown · Non-small Cell Lung Cancer · study chair
- Ph3NCT00874419 · Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 MutationTongji University · completed · Non-small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:43 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.